KIDRON NADAV 4
4 · ORAMED PHARMACEUTICALS INC. · Filed Jan 5, 2026
Insider Transaction Report
Form 4
KIDRON NADAV
DirectorPresident and CEO
Transactions
- Award
Common Stock
2025-12-31+232,640→ 2,919,238 total - Award
Common Stock
2025-12-31+327,000→ 3,246,238 total - Award
Performance Stock Units
2025-12-31+109,000→ 109,000 total→ Common Stock (109,000 underlying)
Holdings
- 126,000(indirect: By wholly-owned corporation)
Common Stock
Footnotes (3)
- [F1]Represents Restricted Stock Units ("RSUs") that vested in full on January 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share ("Common Stock"), of the Issuer.
- [F2]Represents RSUs that will vest in quarterly installments over a three-year period starting January 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer.
- [F3]Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock. The PSUs vest upon the achievement of either (i) the Issuer's Common Stock achieving a specified price per share, or (ii) the achievement of the applicable performance criteria.